Dabrafenib’s drug donation policy

Dabrafenib (Dabrafenib) is a drug used to treat certain types of cancer. It is mainly used to treat malignant melanoma or non-small cell lung cancer with BRAF gene mutations. Its drug donation policies are generally formulated by pharmaceutical manufacturers or hospitals, etc. These policies may vary according to different countries, regions and health care systems. Usually, the drug donation policy refers to providing free or discounted drugs to eligible patients through certain channels. It may be related to the patient's economic conditions, whether they meet treatment guidelines, etc. Patients can consult relevant medical institutions or pharmaceutical companies to learn more.

Dabrafenib's benefits outweigh its risks in cancers harboringBRAF V600 mutations, and when used alone or in combination with tramatinib, it has clinically relevant benefits in patients with advanced non-small cell lung cancer or whose melanoma has spread or is unresectable. It has also been found to be beneficial for patients with advanced melanoma that has been surgically removed. The side effects of dabrafenib are considered acceptable and manageable with appropriate measures.

The original drug of dabrafenib is relatively expensive and has been covered by medical insurance since it was launched in China. Currently only eligible patients are reimbursed. The price of each box of 50mg*120 capsules may be around around 10,000. The Turkish version of the original drug Dabrafenib sold overseas, Specifications 75mg*120 capsules, may cost around 10,000 per box (the price may fluctuate due to exchange rates). There are also relatively cheap generics of dabrafenib sold overseas, and their pharmaceutical ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, Specifications produced by Laos Pharmaceutical Factory The price of 75mg*120 tablets per box may be more than 4,000 yuan (the price may fluctuate due to exchange rates).